International Journal of Cancer Management

Published by: Kowsar

Cost-Utility Analysis of IEV Drug Regimen Versus ESHAP Drug Regimen for the Patients With Relapsed and Refractory Hodgkin and Non-Hodgkin’s Lymphoma in Iran

Nahid Hatam 1 , Mehdi Dehghani 2 , Mostafa Habibian 3 and Abdosaleh Jafari 4 , *
Authors Information
1 School of Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Hematology and Oncology Ward, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Student Research Committee, Department of Health Economics, School of Management and Information ‎Sciences, Shiraz University of Medical Sciences, Shiraz, IR Iran
4 Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, IR Iran
Article information
  • Iranian Journal of Cancer Prevention: October 28, 2015, 8 (5); e4061
  • Published Online: October 27, 2015
  • Article Type: Research Article
  • Received: September 15, 2015
  • Accepted: October 7, 2015
  • DOI: 10.17795/ijcp-4061

To Cite: Hatam N, Dehghani M, Habibian M, Jafari A. Cost-Utility Analysis of IEV Drug Regimen Versus ESHAP Drug Regimen for the Patients With Relapsed and Refractory Hodgkin and Non-Hodgkin’s Lymphoma in Iran, Int J Cancer Manag. 2015 ; 8(5):e4061. doi: 10.17795/ijcp-4061.

Copyright © 2015, Iranian Journal of Cancer Prevention.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Stewart BW, Wild CP. World Cancer Report 2014. 2014;
  • 2. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis. 2010; 31(1): 100-10[DOI][PubMed]
  • 3. Canadian Cancer Statistics. 2008;
  • 4. Altekruse S, Kosary C, Krapcho M, Neyman N, Aminou R, Waldron W. SEER Cancer Statistics Review, 1975-2007. 2010;
  • 5. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 2012; 13(8): 790-801[DOI]
  • 6. Jaffe E, Harris N, Stein H, Vardiman J. WHO classification: Pathology and genetics of tumors of haematopoietic and lymphoid tissues. Ann Oncol. 2001; 13(3): 490-1[DOI]
  • 7. Townsend W, Linch D. Hodgkin's lymphoma in adults. Lancet. 2012; 380(9844): 836-47[DOI]
  • 8. Mousavi S. Executive Guideline for Registering and Reporting Cancer Cases. 2007; : 22
  • 9. Iranian National Cancer . Iranian national cancer registration report, 2010. 2010;
  • 10. The GlobalBurden of Disease. 2008;
  • 11. Khajedaluee M, Dadgarmoghaddam M, Saeedi R, Izadi-Mood Z, Abrishami M, Zamani M. Mortality, Morbidity, Survival, and Burden of Top 9 Cancers in a Developing Country. Razavi Int J Med. 2014; 2(3)
  • 12. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2197-223[DOI]
  • 13. Department of Human Services . Victorian burden of disease study, Mortality and morbidity in 2001. 2005; : 228
  • 14. Mousavi Jarrahi Y, Mousavi Jarrahi A, Mohagheghi MA. The indirect cost of cancer in Tehran, preliminary report. Cancer Bullet. 2010; 2: 60-4
  • 15. Atlanta G. Cancer Facts & Figures 2010. 2010;
  • 16. Davari M, Yazdanpanah F, Aslani A, Hosseini M, Nazari AR, Mokarian F. The Direct Medical Costs of Breast Cancer in Iran: Analyzing the Patient's Level Data from a Cancer Specific Hospital in Isfahan. Int J Prev Med. 2013; 4(7): 748-54[PubMed]
  • 17. Wright MJ, Galea V, Barr RD. Proficiency of balance in children and youth who have had acute lymphoblastic leukemia. Phys Ther. 2005; 85(8): 782-90[PubMed]
  • 18. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992; 327(21): 1478-84[DOI][PubMed]
  • 19. Choi CW, Paek CW, Seo JH, Kim BS, Shin SW, Kim YH, et al. ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma. J Korean Med Sci. 2002; 17(5): 621-4[PubMed]
  • 20. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, et al. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994; 12(6): 1169-76[PubMed]
  • 21. Zinzani PL, Tani M, Molinari AL, Stefoni V, Zuffa E, Alinari L, et al. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haematologica. 2002; 87(8): 816-21
  • 22. Zinzani PL, Barbieri E, Visani G, Gherlinzoni F, Perini F, Neri S, et al. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease. Haematologica. 1994; 79(6): 508-12[PubMed]
  • 23. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5): 365-76[PubMed]
  • 24. Taylor M. What is sensitivity analysis? 2009;
  • 25. Hutubessy R, Chisholm D, Edejer TT. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc. 2003; 1(1): 8[DOI][PubMed]
  • 26. Hackshaw A, Sweetenham J, Knight A. Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma? Br J Cancer. 2004; 90(7): 1302-5[DOI][PubMed]
  • 27. Woronoff-Lemsi MC, Arveux P, Limat S, Deconinck E, Morel P, Cahn JY. Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients. Bone Marrow Transplant. 1997; 20(11): 975-82[DOI][PubMed]
  • 28. Johnston KM, Marra CA, Connors JM, Najafzadeh M, Sehn L, Peacock SJ. Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada. Value Health. 2010; 13(6): 703-11[DOI][PubMed]
  • 29. Leese B, Collin R, Clark DJ. The costs of treating febrile neutropenia in patients with malignant blood disorders. Pharmacoeconomics. 1994; 6(3): 233-9[PubMed]
  • 30. Ray JA, Carr E, Lewis G, Marcus R. An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UK. Value Health. 2010; 13(4): 346-57[DOI][PubMed]
  • 31. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006; 106(10): 2258-66[DOI][PubMed]
  • 32. Hjermstad MJ, Oldervoll L, Fossa SD, Holte H, Jacobsen AB, Loge JH. Quality of life in long-term Hodgkin's disease survivors with chronic fatigue. Eur J Cancer. 2006; 42(3): 327-33[DOI][PubMed]
  • 33. Hasanpour Dehkordi A, Shaaban M. Relationship between cancer characteristics and quality of life in the cancer patients under chemotherapy referred to selected clinic of Tehran university of medical sciences. J Shahrekord Univ Med Sci. 2005; 6(4): 63-71
  • 34. Mols F, Aaronson NK, Vingerhoets AJ, Coebergh JW, Vreugdenhil G, Lybeert ML, et al. Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study. Cancer. 2007; 109(8): 1659-67[DOI][PubMed]
  • 35. Webster K, Cella D. Quality of life in patients with low-grade non-Hodgkin's lymphoma. Oncology (Williston Park, NY). 1998; 12(5): 697-714
  • 36. van Dis FW, Mols F, Vingerhoets AJ, Ferrell B, van de Poll-Franse LV. A validation study of the Dutch version of the Quality of Life-Cancer Survivor (QOL-CS) questionnaire in a group of prostate cancer survivors. Qual Life Res. 2006; 15(10): 1607-12[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments